On the recordMarch 30, 2023
I believe there are three key areas that are really worth focusing on to try to bring sanity here.
Said by
Thomas R. Carper
Source
congress.govEditor's note · Context
Carper outlines key areas to improve transparency and patient benefits in drug pricing.
Share
More from Thomas R. Carper
Jul 25, 2024
I think the greatest way that the Commission can have an impact on that is probably through our rate-making authority.
Jul 10, 2024
We are better off when we hear community concerns at the beginning of the process rather than at the end.
Jun 4, 2024
I usually default to the golden rule, and I think in this case it's a pretty good guide as well.